A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib Oliver Gautschi, MD, Chantal Pauli, MD, Klaus Strobel, MD, Astrid Hirschmann,

Slides:

Advertisements

Similar presentations

Malignant Triton Tumor of the Brachial Plexus Invading the Left Thoracic Inlet: A Rare Differential Diagnosis of Pancoast Tumor Jo Dartnell, BSc, MRCS,

Advertisements

Jeffrey Bradley, MD Journal of Thoracic Oncology

Marked Tumor Response and Fatal Hemoptysis During Radiation for Lung Cancer in a Human Immunodeficiency Virus-Positive Patient Taking Nelfinavir Christopher.

The Role of Extended Cervical Mediastinoscopy in Staging of Non-small Cell Lung Cancer of the Left Lung and a Comparison with Integrated Positron Emission.

FDG PET-CT Aids in the Preoperative Assessment of Patients with Newly Diagnosed Thymic Epithelial Malignancies Marcelo F.K. Benveniste, MD, Cesar A.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography Walter.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Diffusion-weighted magnetic resonance imaging in preoperative assessment of non– small cell lung cancer Hiroaki Nomori, MD, Yue Cong, MD, Masaru Abe,

Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer Ernest Nadal,

BRAF V600E Mutation Is not Always Present as Expected

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH /RO )

Diagnostic Performance of Integrated Positron Emission Tomography/Computed Tomography for Mediastinal Lymph Node Staging in Non-small Cell Lung Cancer:

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma Filippo Gustavo Dall’Olio, MD, Celeste.

Exogenous Lipoid Pneumonia Mimicking Multifocal Bronchogenic Carcinoma

MET-Mutated NSCLC with Major Response to Crizotinib

Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,

Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A

Unexpected Small Bowel Intussusception Caused by Lung Cancer Metastasis on 18F- Fluorodeoxyglucose PET-CT Jeong Won Lee, MD, Seok-Ki Kim, MD, Ji Won Park,

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation Vienna Ludovini, PhD,

Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer

Are We Missing Diagnosis of Large Vessel Vasculitis

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First- line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor.

Nikolaas De Maeyer, MD, Walter De Wever, MD, PhD, Christophe M

Malignant Triton Tumor of the Brachial Plexus Invading the Left Thoracic Inlet: A Rare Differential Diagnosis of Pancoast Tumor Jo Dartnell, BSc, MRCS,

Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer Yukinori Matsuo,

The Role of Extended Cervical Mediastinoscopy in Staging of Non-small Cell Lung Cancer of the Left Lung and a Comparison with Integrated Positron Emission.

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients with Non-small Cell Lung Cancer in Nonoperable Patients.

Metastasectomy in a lung graft using high-flow venovenous extracorporeal lung support in a patient after single lung transplantation Bassam Redwan, MD,

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

The role of positron emission tomography for non-small cell lung cancer Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD Practical.

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer Daniela Weiler, MD, Joachim Diebold, MD, Klaus Strobel, MD, Stefan.

Steve R. Siegal, MD, John G. Hunter, MD, James P. Dolan, MD, MCR

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant.

Pulmonary Metastases from Cervical Adenocarcinoma Regress to a ‘Hole’ Lot of Nothing Michael Guandalini, MBBS (Hons), BPhty, Karin Steinke, MD, MS, PD,

A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch Tadashi Umehara, MD, Masaya Aoki, MD, PhD, Aya Harada,

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Detection of an Asymptomatic Right-Ventricle Cardiac Metastasis from a Small-Cell Lung Cancer by F-18-FDG PET/CT Maria Victoria Orcurto, MD, Angelika.

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage Sara de Cabanyes Candela, MD, Frank.

Matthew Reichert, MD, Eric S. Bensadoun, MD

Shih-Chieh Chang, Cheng-Yu Chang, Chiung-Yu Chen, Chong-Jen Yu

Jeffrey Bradley, MD Journal of Thoracic Oncology

Nicholas W. Choong, MD, Robert S. Hellman, MD

Beware of the “Bronchocele,” Particularly in Patients with a History or Risk Factors for a Mucinous Carcinoma: A Response to the Article “Resection of.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

BRAF V600E Mutation Is not Always Present as Expected

Marianna Koczywas, MD, Mihaela C. Cristea, MD

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Resection of a Solitary Pulmonary Metastasis from Prostatic Adenocarcinoma Misdiagnosed as a Bronchocele: Usefulness of 18F-Choline and 18F-FDG PET/CT

Successful AZD9291 Therapy Based on Circulating T790M

Textiloma on 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: A Wolf in a Sheep's Clothing? David Petermann, MD, Michel Christodoulou,

EBUS-TBNA for the Clarification of PET Positive Intra-Thoracic Lymph Nodes—an International Multi-Centre Experience Robert C. Rintoul, FRCP, PhD, Kurt.

CT (left of images) showing calcified areas and PET (right of images) scans showing increased FDG-PET metabolic activity in the mediastinal mass (A) and.

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma Yu-Li Su, MD Journal of Thoracic.

Super Scan Using Positron Emission Tomography in Lung Cancer Patients

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure Joel P. Womack,

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Presentation transcript:

A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib Oliver Gautschi, MD, Chantal Pauli, MD, Klaus Strobel, MD, Astrid Hirschmann, Gert Printzen, MD, Stefan Aebi, MD, Joachim Diebold, MD Journal of Thoracic Oncology Volume 7, Issue 10, Pages e23-e24 (October 2012) DOI: 10.1097/JTO.0b013e3182629903 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A, CT scan at diagnosis with a tumor in the left lung (long arrow), mediastinal lymph node metastases (short arrow), left pleural effusion (arrowheads), and pericardial effusion; (B) pretreatment FDG-PET/CT with increased FDG uptake (SUV max. 13.3) in the lung tumor (long arrow) and the mediastinal nodes (SUV max. 15.0, short arrow), and pleural effusion (arrowheads); and (C) follow-up FDG-PET/CT after 2 weeks of vemurafenib with decreased uptake in the lung tumor (SUV max. 5.5, long arrow) and in the mediastinal nodes (SUV max. 6.2, short arrow). CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography; SUV max., maximum standardized uptake value. Journal of Thoracic Oncology 2012 7, e23-e24DOI: (10.1097/JTO.0b013e3182629903) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 A, Diagnostic cytology with thyroid transcription factor-1–positive cancer cells and (B) Sanger sequencing read with heterozygous T-A mutation (arrow) in codon 600 of BRAF. C Autopsy with macroscopic appearance of tumor fibrosis in the left lung (arrow) and (D) representative histopathology section with residual tumor cell islet (arrow) surrounded by fibrotic tissue (arrowheads), consistent with significant tumor regression after vemurafenib therapy. Journal of Thoracic Oncology 2012 7, e23-e24DOI: (10.1097/JTO.0b013e3182629903) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions